Target Populations for Novel Triglyceride-Lowering Therapies

Sunday, March 8, 2026

4:21 PM - 4:29 PM EST

Location: Monroe

Speaker(s)

Robert S. Rosenson, MD

Director of Metabolism and Lipids
Mount Sinai Health System
New York, New York, United States

Disclosure(s): 89Bio: Grant/Research Support (Ongoing); Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AstraZeneca Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Kowa Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Merck Pharmaceuticals: Grant/Research Support (Ongoing); NIH: Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharma: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Wolters Kluwer Pharma: Royalties (Ongoing)

Disclosure(s):

Robert S. Rosenson, MD: 89Bio: Grant/Research Support (Ongoing); Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AstraZeneca Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Kowa Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Merck Pharmaceuticals: Grant/Research Support (Ongoing); NIH: Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharma: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Wolters Kluwer Pharma: Royalties (Ongoing)